Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy
Authors
Keywords
Prostate cancer, Cancerous inhibitor of protein phosphatase 2A, Cabazitaxel, Small interfering RNA, Proliferation, Chemoresistance
Journal
TUMOR BIOLOGY
Volume 36, Issue 3, Pages 1589-1594
Publisher
Springer Nature
Online
2014-11-14
DOI
10.1007/s13277-014-2748-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Pathways: PI3K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy
- (2014) M. Chen et al. CLINICAL CANCER RESEARCH
- Castration-resistant prostate cancer: latest evidence and therapeutic implications
- (2014) Daniel L. Suzman et al. Therapeutic Advances in Medical Oncology
- Prostate cancer research in China
- (2013) Shan-Cheng Ren et al. ASIAN JOURNAL OF ANDROLOGY
- CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression
- (2013) Armin Wiegering et al. PLoS One
- Metastatic Hormone Refractory Prostate Cancer
- (2012) Daniel Keizman et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy
- (2012) Yuan-Yuan Qu et al. ASIAN JOURNAL OF ANDROLOGY
- Second-line therapy for castrate-resistant prostate cancer: A literature review
- (2011) S C-H KAO et al. Asia-Pacific Journal of Clinical Oncology
- Increase in CIP2A expression is associated with doxorubicin resistance
- (2011) Yeon A. Choi et al. FEBS LETTERS
- Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
- (2011) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and traditional chemotherapy: A united front against prostate cancer
- (2010) P. Singh et al. CANCER LETTERS
- Update on castrate-resistant prostate cancer: 2010
- (2010) Kiran Lassi et al. CURRENT OPINION IN ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Drug resistance in metastatic castration-resistant prostate cancer
- (2010) Bostjan Seruga et al. Nature Reviews Clinical Oncology
- CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
- (2010) K-F Chen et al. ONCOGENE
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started